| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010990A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | WO2004010982A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 02/05/2004 | WO2004010981A1 Methods and dosage forms for controlled delivery of paliperidone |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010970A1 Formulations and dosage forms for controlled delivery of topiramate |
| 02/05/2004 | WO2004010950A2 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003082255A3 Use of mob-5 in pain |
| 02/05/2004 | WO2003080608A3 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003080580A3 Quinoline derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003073994A3 Methods of treating nerve entrapment syndromes |
| 02/05/2004 | WO2003070167A3 Therapeutic and prophylactic treatment of aging and disorders of aging in humans |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003066067A3 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 02/05/2004 | WO2003055911A8 Cystine-knot fold protein |
| 02/05/2004 | WO2003051348A3 Composition, synthesis and therapeutic applications of polyamines |
| 02/05/2004 | WO2003042397A3 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 02/05/2004 | WO2002094378A3 Increased functional activity and/or expression of abc transporters protects against the loss of dopamine neurons associated with parkinson's disease |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040024218 Novel compounds |
| 02/05/2004 | US20040024210 New compounds |
| 02/05/2004 | US20040024208 Cyclic protein tyrosine kinase inhibitors |
| 02/05/2004 | US20040024207 8'4-'3-(5Fluoro-1h-indol-3yl)propyl!-1-piperazinyl!-2-methyl-2h-1,4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the seotonix reuptake site |
| 02/05/2004 | US20040024203 Imines such as 4-(3-((3-(2,4-dichlorophenyl)propanoyl)amino)-1-(3-(morpholin-4-yl)propyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-5-yl)benzamide, administered for prophylaxis of Alzheimer's disease |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024061 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications |
| 02/05/2004 | US20040024056 Especially Cryptotanshinone and Dihydortanshinone; treatment of chronic hepatitis and hepatocirrhosis |
| 02/05/2004 | US20040024048 Medicaments for treating dementia |
| 02/05/2004 | US20040024043 Administering (-)N-(-)-N phenyl canbamoyleseroline; Alzheimer's disease |
| 02/05/2004 | US20040024040 Inhibitors of GSK-3 and uses thereof |
| 02/05/2004 | US20040024038 GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 02/05/2004 | US20040024036 May take form of gel, ointment or emulsion for local administration, of transdermal patch or of film deposited by a spray, characterized in that it comprises at least one absorption promoter |
| 02/05/2004 | US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals |
| 02/05/2004 | US20040024024 Inhibiting matrix metalloproteinase and aggrecanase activity; for treatment of strokes and neurodegenerative diseases |
| 02/05/2004 | US20040024023 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/05/2004 | US20040024003 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy |
| 02/05/2004 | US20040024002 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 02/05/2004 | US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors |
| 02/05/2004 | US20040023997 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine derivatives; treating parkinson's disease and other central nervous system disorders |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023986 Treating epilepsy, neuropathic pain, and tissue damage form ischemic events; antihypoxic agents |
| 02/05/2004 | US20040023973 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. |
| 02/05/2004 | US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
| 02/05/2004 | US20040023970 Method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I |
| 02/05/2004 | US20040023964 7-phenylimidazo(1,2-b)(1,2,4)triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023960 Mammalian metabolites of the compound 2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3- (4-fluoro) phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo) methylmorpholine which is a tachykinin receptor antagonist as antiemetics |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023927 Bicyclic imidazo-5-yl-amine derivatives |
| 02/05/2004 | US20040023900 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023869 Interleukin-1 inhibitors in the treatment of diseases |
| 02/05/2004 | US20040023862 Newly identified uses of BRS3 polypeptides and polynucleotides encoding such polypeptides, to their use in therapy of ischemia, of neurodegenerative diseases, of memory and attention disorders, and in identifying compounds which may be |
| 02/05/2004 | US20040023859 New melanocortin receptor ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023843 Treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040023335 IL-17 like molecules and uses thereof |
| 02/05/2004 | US20040023312 Based on identification of abnormal behaviour of adenosine A2A receptor, both as regards bond to specific ligands and coupling to adenylate cyclase system characteristic of cells genetically predisposed to develop Huntington's Disease |
| 02/05/2004 | US20040023278 Sialoadhesin family member-2 (SAF-2) |
| 02/05/2004 | US20040022922 Infant formula supplemented with phospholipids |
| 02/05/2004 | US20040022834 Pharmaceutical oxan preparation |
| 02/05/2004 | US20040022783 Binding agents to CD23 |
| 02/05/2004 | US20040022781 Proteins and nucleic acids encoding same |
| 02/05/2004 | US20040022777 Fragments and antagonists of heat shock protein 60 |
| 02/05/2004 | US20040022763 Human recombinant beta-interferon with improved solubility |
| 02/05/2004 | DE10232572A1 Neue 2,5-disubstituierte Pyrimidinderivate New 2,5-disubstituted pyrimidine derivatives |
| 02/05/2004 | DE10232571A1 4-Aminosubstituierte Pyrimidinderivate 4-Amino-substituted pyrimidine derivatives |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | DE10229842A1 Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung Morphinan derivatives and their quaternary ammonium salts substituted in position 14, manufacturing process and use |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494233A1 Formulations and dosage forms for controlled delivery of topiramate |
| 02/05/2004 | CA2494109A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493913A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493629A1 Pramipexole once-daily dosage form |
| 02/05/2004 | CA2493179A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493128A1 Crystalline .beta.2 adrenergic receptor agonist |
| 02/05/2004 | CA2493074A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | CA2492858A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |